Differentiating MYCN-amplified RB1 wild-type retinoblastoma from biallelic RB1 mutant retinoblastoma using MR-based radiomics: a retrospective multicenter case–control study

MLA

Christiaan M. de Bloeme, et al. “Differentiating MYCN-Amplified RB1 Wild-Type Retinoblastoma from Biallelic RB1 Mutant Retinoblastoma Using MR-Based Radiomics: A Retrospective Multicenter Case–control Study.” Scientific Reports, vol. 14, no. 1, Oct. 2024, pp. 1–8. EBSCOhost, https://doi.org/10.1038/s41598-024-76933-6.

APA

Christiaan M. de Bloeme, Robin W. Jansen, Liesbeth Cardoen, Sophia Göricke, Sabien van Elst, Jaime Lyn Jessen, Aparna Ramasubramanian, Alison H. Skalet, Audra K. Miller, Philippe Maeder, Ogul E. Uner, G. Baker Hubbard, Hans Grossniklaus, H. Culver Boldt, Kim E. Nichols, Rachel C. Brennan, Saugata Sen, Mériam Koob, Selma Sirin, … European Retinoblastoma Imaging Collaboration. (2024). Differentiating MYCN-amplified RB1 wild-type retinoblastoma from biallelic RB1 mutant retinoblastoma using MR-based radiomics: a retrospective multicenter case–control study. Scientific Reports, 14(1), 1–8. https://doi.org/10.1038/s41598-024-76933-6

Chicago

Christiaan M. de Bloeme, Robin W. Jansen, Liesbeth Cardoen, Sophia Göricke, Sabien van Elst, Jaime Lyn Jessen, Aparna Ramasubramanian, et al. 2024. “Differentiating MYCN-Amplified RB1 Wild-Type Retinoblastoma from Biallelic RB1 Mutant Retinoblastoma Using MR-Based Radiomics: A Retrospective Multicenter Case–control Study.” Scientific Reports 14 (1): 1–8. doi:10.1038/s41598-024-76933-6.